



# REMARKS

In response to the Notice mailed February 19, 2002, Applicants are submitting herewith formal drawings in compliance with 37 CFR 1.84. The specification has also been amended on page 11, as shown above, to correct the numbering in the BRIEF DESCRIPTION OF THE DRAWINGS to reflect the numbering for formal figures 1A-1C.

A substitute specification in compliance with 37 CFR 1.52 is also submitted herewith. It is requested that this substitute specification be entered in the application file. The substitute specification is identical in content to the application as originally filed on November 2, 2001, but has been re-formatted to comply with proper margin requirements. Accordingly, the undersigned hereby certifies that no new matter is being introduced in the substitute specification.

The amendment to the specification is illustrated in the attached paper entitled "Marked Up Version to Show Changes Made." A clean copy of the amended text is provided above.

It is Applicants' understanding that there is no fee associated with this response, however, in the event that the Patent Office determines that a fee is due in connection with the filing of this document, we hereby authorize the Commissioner to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,  
GENENTECH, INC.

Date: April 17, 2002

By: *Diane L. Marschang*  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE



**MARKED UP VERSION TO SHOW CHANGES MADE**

In the specification:

Please enter the substitute specification comprising 117 pages into the application file.

On page 11, in the paragraph on lines 12-14, the text has been amended as follows:

—Figure 1 (illustrated as Figures 1A-1C) shows the nucleotide sequence of a native sequence human Apo-2 cDNA (SEQ ID NO:2) and its derived amino acid sequence (SEQ ID NO:1). ---

2021030423001